Outlook Therapeutics Inc (OTLK)

[H2R]

Cash/cash equivalents: $70.2 million on 12/31/2021

Financial Highlights for the Fiscal First Quarter Ended December 31, 2021

For the fiscal first quarter ended December 31, 2021, Outlook Therapeutics reported a net loss attributable to common stockholders of $14.5 million, or $0.08 per basic and diluted share, compared to a net loss attributable to common stockholders of $14.5 million, or $0.12 per basic and diluted share, for the same period last year.

In November 2021, Outlook Therapeutics closed a $57.5 million gross proceeds equity offering, including full exercise of underwriter’s option to purchase additional shares, which is expected to provide funding to the anticipated approval of the ONS-5010 BLA expected in the first calendar quarter of 2023.

At December 31, 2021, Outlook Therapeutics had cash and cash equivalents of $70.2 million.

https://seekingalpha.com/pr/18669894-outlook-therapeutics-reports-financial-results-for-first-quarter-fiscal-year-2022-and


They can't be taken down by shenanigans at this stage (See the Lucy Komisar videos:

). I believe they are now past that stage and have a clear line to marketability.

Best of luck with your investments!